InfuSystem Holdings (INFU) Stock Price

InfuSystem Holdings Price

NYSE AMEX·CLOSED
12.27USD-0.21 (-1.70 %)
Market closed

Over the last 18 years InfuSystem Holdings grew revenue by 18.7% annually, reaching 143.44 M USD. Earnings per share have declined at 3.1% per year over the last 17 years. For InfuSystem Holdings, the net margin of 4.6% is up versus 1.4% a few years ago. The consensus 12-month price target for InfuSystem Holdings is 15.30 USD, about 24.7% above where the stock trades today. Of 11 analysts, 10 rate the stock a buy — an overall Buy consensus. The stock trades about 65% above its 52-week low.

InfuSystem Holdings stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of InfuSystem Holdings over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how InfuSystem Holdings stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing InfuSystem Holdings's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

InfuSystem Holdings Stock Price History
DateInfuSystem Holdings Price
8/14/202612.27 USD
8/13/202612.48 USD
8/12/202612.24 USD
8/11/202612.46 USD
8/10/202612.12 USD
8/7/202612.49 USD
8/6/202611.87 USD
8/5/202612.71 USD
8/4/202611.58 USD
8/3/20269.22 USD
7/31/20269.14 USD
7/30/20269.19 USD
7/29/20269.83 USD
7/27/20269.44 USD
7/23/20268.89 USD
7/22/20268.90 USD
7/21/20269.15 USD
7/20/20268.94 USD
7/17/20268.92 USD
7/16/20269.24 USD
7/15/20269.01 USD
7/14/20269.19 USD
7/13/20269.61 USD
7/10/20269.68 USD
7/9/20269.74 USD
7/8/20269.90 USD
7/7/20269.69 USD
7/6/202610.10 USD
7/2/202610.16 USD
7/1/202610.02 USD
6/30/20269.65 USD
6/29/20269.88 USD
6/26/202610.05 USD
6/25/20269.05 USD
6/24/20269.15 USD
6/23/20269.08 USD
6/22/20269.20 USD
6/18/20269.42 USD
6/17/20268.75 USD
6/16/20268.80 USD
6/15/20268.80 USD
6/12/20269.14 USD
6/11/20269.05 USD
6/10/20269.05 USD
6/9/20269.01 USD
6/8/20269.01 USD
6/5/20269.24 USD
6/4/20269.12 USD
6/3/20269.03 USD
6/2/20268.88 USD
6/1/20268.95 USD
5/29/20269.07 USD
5/28/20269.06 USD
5/27/20269.25 USD
5/26/20269.51 USD
5/22/20269.66 USD
5/21/20269.94 USD
5/20/202610.16 USD
5/19/20269.67 USD
5/18/20268.90 USD
5/15/20268.77 USD
5/14/20268.61 USD
5/13/20268.21 USD
5/12/20268.41 USD
5/11/20268.37 USD
5/8/20268.41 USD
5/7/20268.97 USD
5/6/202610.14 USD
5/5/202610.62 USD
5/4/202610.39 USD
5/1/202610.37 USD
4/30/202610.13 USD
4/29/20269.83 USD
4/28/202610.18 USD
4/27/202610.66 USD
4/24/202610.34 USD
4/23/202610.33 USD
4/22/202610.41 USD
4/21/202610.30 USD
4/20/202610.79 USD
4/17/202610.58 USD
4/16/202610.23 USD
4/15/202610.20 USD
4/14/20269.99 USD
4/13/20269.73 USD
4/10/20269.38 USD
4/9/20269.62 USD
4/8/20269.47 USD
4/7/20269.36 USD
4/6/20269.43 USD
4/2/20269.29 USD
4/1/20269.30 USD
3/31/20269.23 USD
3/30/20269.35 USD
3/27/20269.54 USD
3/26/20269.70 USD
3/25/20269.79 USD
3/24/20269.69 USD
3/23/20269.60 USD
3/20/20269.09 USD
3/19/20269.55 USD
3/18/20269.62 USD
3/17/20269.83 USD
3/16/20269.57 USD
3/13/20269.31 USD
3/12/20269.39 USD
3/11/20269.61 USD
3/10/20269.68 USD
3/9/20269.83 USD
3/6/20269.48 USD
3/5/20269.68 USD
3/4/20269.60 USD
3/3/20269.18 USD
3/2/20269.29 USD
2/27/20268.77 USD
2/26/20269.19 USD
2/25/20268.56 USD
2/24/20268.60 USD
2/23/20267.58 USD
2/20/20267.95 USD
2/19/20267.90 USD
2/18/20267.75 USD
2/17/20267.60 USD
2/13/20267.54 USD
2/12/20267.42 USD
2/11/20267.61 USD
2/10/20267.61 USD
2/9/20267.66 USD
2/6/20267.72 USD
2/5/20267.57 USD
2/4/20267.76 USD
2/3/20268.29 USD
2/2/20268.24 USD
1/30/20268.26 USD
1/29/20268.05 USD
1/28/20268.11 USD
1/27/20268.48 USD
1/26/20268.65 USD
1/23/20268.48 USD
1/22/20268.65 USD
1/21/20268.62 USD
1/20/20268.40 USD
1/16/20268.78 USD
1/15/20268.60 USD
1/14/20268.72 USD
1/13/20268.51 USD
1/12/20268.74 USD
1/9/20268.67 USD
1/8/20268.97 USD
1/7/20268.91 USD
1/6/20268.77 USD
1/5/20268.82 USD
1/2/20268.39 USD
12/31/20258.97 USD
12/30/20258.91 USD
12/29/20258.96 USD
12/26/20258.96 USD
12/24/20259.11 USD
12/23/20259.04 USD
12/22/20259.16 USD
12/19/20259.20 USD
12/18/20259.52 USD
12/17/20259.32 USD
12/16/20259.29 USD
12/15/20259.24 USD
12/12/20259.24 USD
12/11/20259.21 USD
12/10/20259.11 USD
12/9/20259.13 USD
12/8/20258.75 USD
12/5/20258.89 USD
12/4/20258.96 USD
12/3/20259.34 USD
12/2/20258.97 USD
12/1/20259.27 USD
11/28/20259.28 USD
11/26/20259.25 USD
11/25/20259.63 USD
11/24/20259.51 USD
11/21/20259.46 USD
11/20/20259.22 USD
11/19/20259.28 USD
11/18/20259.31 USD
11/17/20259.32 USD
11/14/20259.51 USD
11/13/202510.16 USD
11/12/202510.43 USD
11/11/202510.45 USD
11/10/202510.09 USD
11/7/20259.92 USD
11/6/202510.29 USD
11/5/202510.00 USD
11/4/20259.46 USD
11/3/202510.40 USD
10/31/202510.36 USD
10/30/202510.00 USD
10/29/202510.52 USD
10/28/202510.45 USD
10/27/202510.01 USD
10/24/202510.13 USD
10/23/202510.06 USD
10/22/20259.79 USD
10/21/20259.68 USD
10/20/20259.60 USD
10/17/20259.00 USD
10/16/20259.29 USD
10/15/20259.51 USD
10/14/20259.14 USD
10/13/20259.22 USD
10/10/20259.23 USD
10/9/20259.61 USD
10/8/20259.82 USD
10/7/202510.17 USD
10/6/202510.50 USD
10/3/202510.36 USD
10/2/202510.22 USD
10/1/202510.27 USD
9/30/202510.36 USD
9/29/202510.50 USD
9/26/202510.34 USD
9/25/202510.08 USD
9/24/202510.25 USD
9/23/202510.22 USD
9/22/202510.41 USD
9/19/202510.00 USD
9/18/202510.04 USD
9/17/20259.78 USD
9/16/202510.10 USD
9/15/202510.16 USD
9/12/20259.99 USD
9/11/202510.13 USD
9/10/202510.10 USD
9/9/202510.42 USD
9/8/202510.26 USD
9/5/202510.16 USD
9/4/202510.63 USD
9/3/202510.55 USD
9/2/202510.58 USD
8/29/202510.78 USD
8/28/202510.73 USD
8/27/202510.34 USD
8/26/20259.92 USD
8/25/20259.87 USD
8/22/20259.57 USD
8/21/20259.61 USD
8/20/20259.60 USD
8/19/20259.62 USD
8/18/20259.53 USD
Access this data via the Eulerpool API
Get Free API Key

InfuSystem Holdings Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
102.38 M USD
2.82 M USD
1.42 M USD
Jan 1, 2022
109.91 M USD
1.65 M USD
18,000.00 USD
Jan 1, 2023
125.79 M USD
4.09 M USD
872,000.00 USD
Jan 1, 2024
134.86 M USD
6.89 M USD
2.35 M USD
Jan 1, 2025
143.44 M USD
11.92 M USD
6.63 M USD
Jan 1, 2026 (e)
144.77 M USD
22.53 M USD
9.23 M USD
Jan 1, 2027 (e)
155.71 M USD
24.24 M USD
11.83 M USD
Jan 1, 2028 (e)
165.35 M USD
25.74 M USD
0.00 USD

InfuSystem Holdings Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 17, 2026, 5:22 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
20132014201520162017201820192020202120222023202420252026e2027e2028e
62.0066.0072.0070.0071.0067.0081.0097.00102.00109.00125.00134.00143.00144.00155.00165.00
6.906.459.09-2.781.43-5.6320.9019.755.156.8614.687.206.720.707.646.45
69.3571.2170.8362.8660.5658.2156.7959.7956.8655.0550.4052.2455.9455.9455.9455.94
43.0047.0051.0044.0043.0039.0046.0058.0058.0060.0063.0070.0080.0080.5686.7192.31
5.009.008.00–-3.00–3.008.002.001.004.006.0011.0022.0024.0025.00
8.0613.6411.11–-4.23–3.708.251.960.923.204.487.6915.2815.4815.15
1.003.003.00–-20.00-1.001.0017.001.00––2.006.009.0011.00–
-200.00200.00–––-95.00-200.001,600.00-94.12–––200.0050.0022.22–
21.9722.8322.9322.6722.7819.5621.3221.7322.0721.3921.7621.7121.0721.0721.0721.07
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales InfuSystem Holdings generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue InfuSystem Holdings retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare InfuSystem Holdings's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares InfuSystem Holdings has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against InfuSystem Holdings's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

InfuSystem Holdings stock margins

The InfuSystem Holdings margin analysis displays the gross margin, EBIT margin, as well as the profit margin of InfuSystem Holdings. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for InfuSystem Holdings.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
57.17 %
2.75 %
1.39 %
Jan 1, 2022
55.10 %
1.50 %
0.02 %
Jan 1, 2023
50.17 %
3.25 %
0.69 %
Jan 1, 2024
52.20 %
5.11 %
1.74 %
Jan 1, 2025
55.98 %
8.31 %
4.62 %
Jan 1, 2026 (e)
55.98 %
15.57 %
6.37 %
Jan 1, 2027 (e)
55.98 %
15.57 %
7.60 %
Jan 1, 2028 (e)
55.98 %
15.57 %
0.00 %

InfuSystem Holdings Stock Revenue, EBIT, Earnings per Share

The InfuSystem Holdings earnings per share therefore indicates how much revenue InfuSystem Holdings has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
4.64 USD
0.13 USD
0.06 USD
Jan 1, 2022
5.14 USD
0.08 USD
0.00 USD
Jan 1, 2023
5.78 USD
0.19 USD
0.04 USD
Jan 1, 2024
6.21 USD
0.32 USD
0.11 USD
Jan 1, 2025
6.81 USD
0.57 USD
0.31 USD
Jan 1, 2026 (e)
6.67 USD
1.07 USD
0.43 USD
Jan 1, 2027 (e)
7.17 USD
1.15 USD
0.55 USD
Jan 1, 2028 (e)
7.62 USD
1.22 USD
0.00 USD

InfuSystem Holdings business model & stock analysis

InfuSystem Holdings Inc. is a leading provider of outpatient infusion therapy management solutions for patients and healthcare facilities in the United States. The company was founded in 2005 and is headquartered in Madison Heights, Michigan. It has experienced significant growth in recent years and is expanding its services nationwide.

InfuSystem Holdings SWOT Analysis

Strengths

InfuSystem Holdings Inc has a strong market presence and brand recognition in the healthcare industry, leading to a loyal customer base.

The company has a wide range of high-quality and technologically advanced infusion pumps, ensuring a competitive advantage over rivals.

InfuSystem has established strategic partnerships with major healthcare providers, enabling them to secure long-term contracts and stable revenue streams.

Weaknesses

The company heavily relies on third-party suppliers for the production and maintenance of their infusion pumps, leading to potential supply chain disruptions and increased costs.

InfuSystem faces regulatory and compliance challenges in the highly regulated healthcare industry, which may result in increased expenses and legal risks.

The company lacks diversification in its product portfolio, primarily focusing on infusion pumps, which makes them vulnerable to market fluctuations and shifts in customer demand.

Opportunities

The growing demand for home healthcare services presents an opportunity for InfuSystem to expand its customer base and revenue by providing infusion pump solutions for at-home treatments.

The increasing prevalence of chronic diseases, such as cancer and diabetes, creates a larger market for infusion pumps, allowing InfuSystem to tap into new patient segments.

InfuSystem can explore international markets and strategic partnerships to expand its global presence and increase market share.

Threats

Intense competition within the healthcare industry poses a threat to InfuSystem's market share and profitability.

Changes in healthcare reform and policies may impact reimbursement rates for InfuSystem's products and services, potentially reducing their revenue.

The ongoing COVID-19 pandemic presents challenges in terms of disrupted supply chains, reduced healthcare facility operations, and financial uncertainties.

InfuSystem Holdings Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

InfuSystem Holdings Employees
Details
Date
InfuSystem Holdings Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

InfuSystem Holdings Segments

InfuSystem Holdings Revenue by Segment (1/2)

  • 3 Years

  • Max

Third-Party Payer Rentals
Direct Payer Rentals
Services Product Sales
Product Sales
Service
Services
Details
Date
Third-Party Payer Rentals
Direct Payer Rentals
Services Product Sales
Product Sales
Service
Services
Jan 1, 2021
52.85 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
4.72 M USD
Jan 1, 2022
55.54 M USD
13.24 M USD
15.36 M USD
107,000.00 USD
7.07 M USD
0.00 USD

InfuSystem Holdings Revenue by Segment (2/2)

  • 3 Years

  • Max

Direct Payer Rentals
Product Sales
Details
Date
Direct Payer Rentals
Product Sales
Jan 1, 2021
16.80 M USD
15.30 M USD
Jan 1, 2022
0.00 USD
0.00 USD

InfuSystem Holdings Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

InfuSystem Holdings historical P/E ratio, EBIT multiple, and P/S ratio

InfuSystem Holdings annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

InfuSystem Holdings shares outstanding

The number of shares of InfuSystem Holdings was 21.07 M in 2025. This indicates how many shares InfuSystem Holdings is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
22.07 M Stocks
Jan 1, 2022
21.39 M Stocks
Jan 1, 2023
21.76 M Stocks
Jan 1, 2024
21.71 M Stocks
Jan 1, 2025
21.07 M Stocks
Jan 1, 2026 (e)
21.07 M Stocks
Jan 1, 2027 (e)
21.07 M Stocks
Jan 1, 2028 (e)
21.07 M Stocks

Current InfuSystem Holdings forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
90.91 % (10)
Hold
9.09 % (1)
Sell
0.00 % (0)
12M Price Target
15.30
Last Price
12.27
Currency
USD
12M Return Potential
24.69 %
LTM Return
0 %

InfuSystem Holdings Analyst Rating Actions

DateFirmActionRating
2/25/2026
Roth Capital
Roth Capital
MaintainedBuy
11/5/2025
Roth Capital
Roth Capital
MaintainedBuy
4/26/2021
Northland Capital Markets
Northland Capital Markets
MaintainedOutperform
8/31/2020
Craig-Hallum
Craig-Hallum
MaintainedBuy

InfuSystem Holdings Earnings Calls

2025

InfuSystem Holdings Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/6/20260.11USD-37.08 MUSD-2026 Q2
5/6/20260.03USD-35.03 MUSD-2026 Q1
3/2/20260.07USD-37.41 MUSD-2025 Q4
11/13/20240.06USD-35.17 MUSD-2024 Q3
5/2/20240.03USD-32.84 MUSD-2024 Q1
3/13/2024-USD-30.60 MUSD-2023 Q4
8/2/20230.03USD-30.26 MUSD-2023 Q2
5/3/20230.02USD-29.51 MUSD-2023 Q1
2/8/20230.04USD-31.60 MUSD-2022 Q4
11/8/20220.01USD-28.45 MUSD-2022 Q3

EESG©

Eulerpool ESG Scorecard© for the InfuSystem Holdings stock

50/100
54
Environment
59
Social
37
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

InfuSystem Holdings shareholder structure

% Name
5.86117%
AWM Investment Company, Inc.
AWM Investment Company, Inc.
4.58272%
Minerva Advisors LLC
Minerva Advisors LLC
4.41161%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
4.19387%
First Eagle Investment Management, L.L.C.
First Eagle Investment Management, L.L.C.
4.04704%
Punch & Associates Investment Management, Inc.
Punch & Associates Investment Management, Inc.
3.25469%
Meros Investment Management, LP
Meros Investment Management, LP
...

InfuSystem Holdings Beneficial Ownership Filings (SEC 13D/G)

Free Float
92.7%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
10.30%
46-3724228
46-3724228
SEC ↗
10.30%
45-2531394
45-2531394
SEC ↗
10.30%
27-1033220
27-1033220
SEC ↗
10.30%
20-4921646
20-4921646
SEC ↗
10.30%
20-2141854
20-2141854
SEC ↗
9.20%
Kleinheinz Capital Partners LDC
Kleinheinz Capital Partners LDC
SEC ↗
9.20%
Global Undervalued Securities Fund (QP), L.P.
Global Undervalued Securities Fund (QP), L.P.
SEC ↗
9.20%
Global Undervalued Securities Fund, Ltd.
Global Undervalued Securities Fund, Ltd.
SEC ↗
8.80%
Minerva Advisors LLC Minerva Group, LP Minerva GP, LP Minerva GP, Inc. David P. Cohen
Minerva Advisors LLC Minerva Group, LP Minerva GP, LP Minerva GP, Inc. David P. Cohen
SEC ↗
8.10%
Ryan J. Morris
Ryan J. Morris
SEC ↗

InfuSystem Holdings Executives and Management Board

10 members · avg. age 55 · 20 % women

CL

Ms. Carrie Lachance (48)

President, Chief Executive Officer, Director · since 2019

1.29 M USD

Management

BS

Mr. Barry Steele (54)

Chief Financial Officer, Executive Vice President

1.25 M USD
JF

Mr. Jerod Funke (50)

Chief Human Resources Officer, Executive Vice President

–
AC

Mr. Addam Chupa (46)

Executive Vice President, Chief Information Officer

–
JD

Mr. Joe Dorame

Investor Relations · since 2015

–

Board of Directors

SS

Mr. Scott Shuda (59)

Director

195,716.00 USD
PG

Mr. Paul Gendron (63)

Independent Director

175,352.00 USD
BH

Ms. Beverly Huss (65)

Independent Director

141,334.00 USD
KE

Mr. Kenneth Eichenbaum (48)

Independent Director

138,197.00 USD
RH

Mr. Ronald Hundzinski (66)

Independent Chairman of the Board

63,702.00 USD

InfuSystem Holdings Supply Chain

InfuSystem Holdings Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
6 companies
#NameTrend
1
Smiths Group
Supplier·Industrial Conglomerates·GB
0.69
0.44
0.06
0.63
0.41
0.56
#NameTrend
1
Becton, Dickinson
Supplier·Health Care Equipment & Supplies·US
0.62
0.58
0.48
-0.28
-0.53
-0.32
2
Repro Med Systems
Supplier·Health Care Equipment & Supplies·US
-0.12
-0.16
0.51
0.56
0.70
-0.08
3
ICU Medical
Supplier·Health Care Equipment & Supplies·US
0.37
-0.17
0.58
0.39
-0.04
0.02
4
Cardinal Health
Supplier·Health Care Providers & Services·US
0.66
-0.21
-0.64
-0.83
-0.34
0.19
5
Baxter Intl
Supplier·Health Care Equipment & Supplies·US
0.22
0.46
0.77
0.76
0.33
0.24

Frequently asked questions about InfuSystem Holdings

InfuSystem Holdings Inc operates as a leading provider of infusion pumps and related services for the healthcare industry. The company's business model primarily revolves around offering a comprehensive range of infusion pumps, equipment, and consumables for various medical treatments. InfuSystem specializes in providing infusion services for oncology practices, as well as other healthcare facilities. By focusing on delivering high-quality products and exceptional customer service, the company aims to meet the unique needs of healthcare providers and ensure efficient and effective patient care. InfuSystem Holdings Inc continuously strives to enhance its product offerings and expand its market reach to drive growth and contribute to positive patient outcomes.

InfuSystem Holdings Inc primarily operates in the healthcare and medical equipment industry.

The main competitors of InfuSystem Holdings Inc in the market include Option Care Health Inc and BioScrip Inc.

InfuSystem Holdings Inc, established in 2005, is a leading provider of infusion pumps and related services in the healthcare industry. With headquarters in Michigan, the company primarily caters to patients and healthcare facilities across the United States and Canada. InfuSystem offers an extensive range of infusion pumps, along with clinical and biomed support, thereby ensuring efficient and cost-effective delivery of medications needed for patient care. Over the years, the company has successfully expanded its product and service portfolio, partnering with medical professionals and hospitals to enhance patient outcomes. InfuSystem Holdings Inc has consistently demonstrated its commitment to revolutionizing healthcare delivery through innovative solutions.

InfuSystem Holdings Inc. has achieved significant milestones since its establishment. Some notable achievements include expanding its presence across the United States, enhancing its product portfolio with innovative offerings, and establishing strategic partnerships. The company has successfully gained a strong reputation for providing high-quality infusion pumps and related services to healthcare facilities and practitioners. InfuSystem Holdings Inc. has also demonstrated consistent growth and financial performance, consolidating its position as a leading provider in the medical device industry. These accomplishments exemplify the company's commitment to delivering excellent products, services, and value to its customers and stakeholders.

InfuSystem Holdings Inc, a leading provider of infusion pumps and related services, primarily operates in the United States. With offices strategically located across the nation, InfuSystem serves healthcare providers in various states and regions. The company focuses on delivering exceptional medical equipment management and infusion therapy services, supporting healthcare professionals and patients in enhancing the quality and ease of care. InfuSystem's strong presence in the United States enables them to maintain close relationships with healthcare institutions, ensuring efficient and reliable delivery of their innovative solutions.

InfuSystem Holdings Inc represents a strong commitment to delivering high-quality, patient-centric healthcare solutions. Their corporate philosophy revolves around providing comprehensive support and innovative technology to healthcare providers. With a focus on enhancing patient care, InfuSystem offers a wide range of infusion pumps, supplies, and services. Through their dedication to exceptional customer service, advanced technology, and improving patient outcomes, InfuSystem Holdings Inc continuously strives to be a reliable partner in the healthcare industry.

Analysts currently set an average price target of 14.48 USD for the InfuSystem Holdings stock (median: 15.30 USD), implying +18.0 % versus the latest price. The consensus is based on 11 analyst ratings.

InfuSystem Holdings Analyst Price Targets 2026

11 analysts currently rate the InfuSystem Holdings stock: 10 recommend buying, 1 holding and 0 selling. For 2026, analysts expect InfuSystem Holdings to generate revenue of 144.77 M USD and earnings per share of 0.44 USD.

InfuSystem Holdings Analyst Price Targets 2026

Converted at the current exchange rate, the InfuSystem Holdings share trades at 10.60 EUR (12.27 USD).

The InfuSystem Holdings share (INFU) is listed on 2 stock exchanges, including: Frankfurt (1TZ.F).

InfuSystem Holdings Inc is a leading provider of oncology equipment and services. The company offers a wide range of products and services aimed at improving the effectiveness of cancer treatment, improving patient care, and enabling cost savings. The company operates in two main areas: infusion therapy and oncology management. The infusion therapy division includes the rental and sale of infusion pumps and accessories. These pumps are used to administer medications, fluids, and nutrients directly into the patient's bloodstream. InfuSystem offers portable pumps, among other things, that allow patients to conveniently perform their treatment from home. The pumps are equipped with state-of-the-art technology to ensure precise dosing and monitoring of the infusion process. InfuSystem's oncology management program focuses on the management and monitoring of chemotherapy-related side effects, as well as online diagnostics. The program provides close monitoring to ensure that the patient's treatment achieves the best possible results. InfuSystem works closely with treating physicians and nurses to ensure that patients receive the best possible care. In addition to these main activities, InfuSystem also offers a range of complementary products and services, including clinical consulting, education and training, disposable items, and an online platform with comprehensive training materials. These complementary services are designed to improve the effectiveness of cancer treatment and optimize patient care. To deliver its services, InfuSystem has built a network of healthcare customers who support the company as partners in treating their patients. The company's customer base includes a wide range of healthcare facilities, including hospitals, oncology practices, outpatient infusion centers, and other outpatient healthcare providers. Through strategic partnerships and acquisitions, InfuSystem has expanded its reach and ability to provide integrated solutions in the oncology market. Overall, InfuSystem has developed a business model focused on improving cancer treatment, patient care, and cost control. The company offers a wide range of products and services to meet the needs of its healthcare customers and has thus laid a strong foundation for future growth.

The expected revenue of InfuSystem Holdings is 144.77 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of InfuSystem Holdings is 9.23 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of InfuSystem Holdings is currently 28.02. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the InfuSystem Holdings stock.

The price-to-sales ratio (P/S) of InfuSystem Holdings is currently 1.79. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the InfuSystem Holdings stock.

The Eulerpool Quality Score for InfuSystem Holdings is 4/10.

The ISIN of InfuSystem Holdings is US45685K1025. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of InfuSystem Holdings is A0NA9V. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of InfuSystem Holdings is INFU. The ticker symbol is used to trade InfuSystem Holdings shares on the stock exchange.

InfuSystem Holdings paid dividends every year for the past 0 years.

InfuSystem Holdings is assigned to the 'Health' sector.

The dividends of InfuSystem Holdings are distributed in USD.

All fundamentals and in-depth analysis of InfuSystem Holdings

Our stock analysis for InfuSystem Holdings stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of InfuSystem Holdings. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

InfuSystem Holdings Stock
InfuSystem Holdings Revenue→
InfuSystem Holdings Stock
InfuSystem Holdings Net Income→
InfuSystem Holdings Stock
InfuSystem Holdings P/E→
InfuSystem Holdings Stock
InfuSystem Holdings P/S→
InfuSystem Holdings Stock
InfuSystem Holdings EBIT→
InfuSystem Holdings Stock
InfuSystem Holdings Dividend→
InfuSystem Holdings Stock
InfuSystem Holdings Directors Dealings→
InfuSystem Holdings Stock
InfuSystem Holdings Stocks→
InfuSystem Holdings Stock
InfuSystem Holdings Market capitalization→
InfuSystem Holdings Stock
InfuSystem Holdings Debt→
InfuSystem Holdings Stock
InfuSystem Holdings Liabilities→
InfuSystem Holdings Stock
InfuSystem Holdings Equity→
InfuSystem Holdings Stock
InfuSystem Holdings AAQS→
InfuSystem Holdings Stock
InfuSystem Holdings Employees→
InfuSystem Holdings Stock
InfuSystem Holdings ROE→
InfuSystem Holdings Stock
InfuSystem Holdings ROA→
InfuSystem Holdings Stock
InfuSystem Holdings ROCE→
InfuSystem Holdings Stock
InfuSystem Holdings News→
InfuSystem Holdings Stock
InfuSystem Holdings Analyst Price Targets→

Health Stocks

Ingen TechnologiesInflaRxInhalation Sciences SwedenInfinium PharmachemInhibikase TherapeuticsInfinity PharmaceuticalsInhibitor TherapeuticsInfinitt Healthcare CoInhibrx BiosciencesInfant Bacterial TherapeuticsINIFY LaboratoriesIndraprastha Medical CorporationAll Stocks A–Z →